Each laboratory will also continue to participate in the UK NEQAS molecular genetic analysis of CRC external quality assurance (EQA) scheme; this currently (as of 2013) includes analyses for KRAS, NRAS, BRAF and PIK3CA. With all these measures in place, we are confident that molecular testing will continue to be delivered with high and exacting standards from these designated testing laboratories. Here, NRAS is linked to colorectal carcinoma.